Columbia University

Technology Ventures

Blood-brain Permeant PDE5 Inhibitors

Blood-brain permeant PDE5 inhibitors: Dr. Ottavio Arancio, Professor of Pathology and Cell Biology, is spinning out a company to commercialize blood-brain permeant phosphodiesterase 5 (PDE5) inhibitors to restore synaptic dysfunction underlying cognitive decline associated with Alzheimer’s disease and other neurological disorders. Extensive studies with selective inhibition of PDE5 demonstrates rescue of synaptic and memory defects due to ABeta and tau elevation. An extensive patent portfolio exists covering new PDE5 inhibitors and their methods of use.

To learn more about this opportunity, contact:

Ron Katz
Associate Director of Manhattanville Licensing
ron.katz@columbia.edu